Oral tadalafil and dapagliflozin in diabetic fatty liver patients to examin there role in reducing insulin resistance

COMPARISON OF THE REDUCTION of INSULIN RESISTANCE BY TADALAFIL AND DAPAGLIFLOZIN AS A COMBINATION THERAPY OVER DAPAGLIFLOZIN MONOTHERAPY IN DIABETIC NAFLD PATIENT :A RANDOMISED CONTROL TRIAL - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/072729

Enrollment

Registered

2024-08-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Intervention1: Tab.TADALAFIL 10mg od and Tab.dapagliflozin 10mg od for 3 months: Group A Tablet TADALAFIL 10mg od , tablet dapagliflozin 10mg od for 3 months End of 3 months fib 4 score and insulin r

Eligibility

Inclusion criteria

Inclusion criteria: Type 2 DM Fib 4 score 1.3 USG abdomen showing fatty liver

Exclusion criteria

Exclusion criteria: Heart failure patient CAD on nitrate Urinary tract infection Allergic to drugs

Design outcomes

Primary

Measure	Time frame
Group A will have more reduction in insulin resistance than group BTimepoint: 3 months	—

Secondary

Measure	Time frame
Reduction in ALT thereby reduction in fib 4 scoreTimepoint: Three months	—

Countries

India

Contacts

Public ContactDeepankumar T

Srm medical college hospital and research centre

madhavak1@srmist.edu.in9791099185

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026